SELLAS Life Sciences (SLS) Receivables - Net (2013 - 2022)
SELLAS Life Sciences (SLS) posted quarterly Receivables - Net of $1.0 million for Q1 2022, down 44.99% quarter-over-quarter from $1.8 million in Q2 2015.
SELLAS Life Sciences (SLS) Receivables - Net (2013 - 2022) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Receivables - Net for 4 consecutive years, with $1.0 million the latest figure, recorded in Q1 2022.
- In Q1 2022, Receivables - Net changed N/A year-over-year to $1.0 million; the TTM figure through Mar 2022 stood at $1.0 million (changed N/A YoY), while the FY2014 annual figure was $1.8 million, down 50.07% from the prior year.
- Receivables - Net retreated to $1.0 million in Q1 2022 per SLS's latest filing, from $1.8 million in the prior quarter.
- Across five years, Receivables - Net topped out at $1.0 million in Q1 2022 and bottomed at $1.0 million in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 1.00 Mn |
| Mar 31, 2022 | 1.00 Mn |
| Jun 30, 2015 | 1.82 Mn |
| Jun 30, 2015 | 1.82 Mn |
| Mar 31, 2015 | 1.06 Mn |
| Mar 31, 2015 | 1.06 Mn |
| Dec 31, 2014 | 1.84 Mn |
| Dec 31, 2014 | 1.84 Mn |
| Sep 30, 2014 | 1.44 Mn |
| Sep 30, 2014 | 1.44 Mn |
| Jun 30, 2014 | 2.15 Mn |
| Jun 30, 2014 | 2.15 Mn |
| Mar 31, 2014 | 1.47 Mn |
| Mar 31, 2014 | 1.47 Mn |
| Dec 31, 2013 | 3.68 Mn |
| Dec 31, 2013 | 3.68 Mn |
| Sep 30, 2013 | 1.54 Mn |
| Sep 30, 2013 | 1.54 Mn |